Related Experiment Video
Updated: May 26, 2026

A Magnetic Resonance Imaging Protocol for Stroke Onset Time Estimation in Permanent Cerebral Ischemia
Published on: September 16, 2017
Brain Atrophy and White Matter Changes Grading Agreement on NCCT and MRI in Ischemic Stroke
William Betzner1, Nishita Singh2, Ibrahim Alhabli3
1Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada. william.betzner@ucalgary.ca.
Purpose:
Brain frailty measures like atrophy and white matter changes (WMC) are becoming increasingly relevant in stroke outcome prediction but are conventionally thought to be best seen on MRI compared to CT. We assessed agreement between baseline CT vs follow-up MRI ratings for brain atrophy and WMC; and compared their discriminative ability for 90-day functional outcomes in acute ischemic stroke.
Methods:
In this post-hoc, observational analysis of baseline CT and follow-up MRI data from the Alteplase compared to Tenecteplase (AcT) randomised-controlled trial, experts assessed brain atrophy, periventricular and deep WMC using established visual-rating scales. Binary agreement (none-mild vs. moderate-severe) and agreement across the full scores between atrophy and WMC measures on CT and MRI were calculated using Gwet's agreement coefficient (AC1). Logistic regression estimated discrimination for 90-day modified Rankin Scale (mRS) 0-1. Agreement of AUCs for CT and MRI models were compared using DeLong's test.
Results:
Among 1577 AcT participants, 491(31.1%) had interpretable CT and MRI. Binary agreement was substantial for periventricular (AC1 = 0.70) and total WMC (AC1 = 0.68) scores, Koedam scale (AC1 = 0.76) and frontal atrophy (AC1 = 0.80). Almost perfect agreement (AC1:0.81-0.97) was found for deep WMC (AC1 = 0.85), and the other atrophy scores (AC1 = 0.81-0.97). There was no significant difference between NCCT or MRI in discriminating 90-day mRS 0-1 for any measures.
Conclusions:
CT ratings of brain atrophy and WMC by experts have substantial to almost-perfect agreement compared to MRI. Both achieve similar discrimination of 90-day functional outcomes. This implies the reasonable use of CT scans in evaluating brain frailty measures in clinical practice and stroke trials.
Insights
Computed tomography (CT) scans show substantial agreement with MRI for assessing brain atrophy and white matter changes (WMC). Both imaging methods effectively predict 90-day stroke outcomes, suggesting CT is a viable tool in stroke research and practice.
Area of Science:
- Neurology
- Radiology
- Stroke Medicine
Background:
- Brain frailty measures, including atrophy and white matter changes (WMC), are crucial for predicting stroke outcomes.
- Magnetic resonance imaging (MRI) is traditionally considered superior for visualizing these changes compared to computed tomography (CT).
Purpose of the Study:
- To assess the agreement between baseline CT and follow-up MRI for brain atrophy and WMC.
- To compare the discriminative ability of CT versus MRI in predicting 90-day functional outcomes after acute ischemic stroke.
Main Methods:
- Observational analysis of CT and MRI data from the Alteplase compared to Tenecteplase (AcT) trial.
- Expert visual rating of brain atrophy and WMC using established scales.
- Gwet's agreement coefficient (AC1) for binary and full score agreement.
- Logistic regression and DeLong's test for comparing discriminative ability (90-day mRS 0-1).
Main Results:
- Substantial to almost-perfect agreement (AC1: 0.68-0.97) between CT and MRI for brain atrophy and WMC ratings.
- No significant difference in the ability of CT versus MRI to discriminate 90-day functional outcomes (mRS 0-1).
Conclusions:
- Expert CT ratings of brain atrophy and WMC demonstrate high agreement with MRI findings.
- CT and MRI show comparable efficacy in predicting 90-day functional outcomes in acute ischemic stroke.
- CT is a reasonable tool for evaluating brain frailty in clinical practice and stroke trials.
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies for Cardiovascular System IV: CMRI

